Drug intelligence / Profile preview

Elravie Balance

Development stage: Unknown
Lead developer: Humedix
Modality: Small Molecules
Administration: Intradermal

Overview

Elravie Balance is a non-crosslinked hyaluronic acid (HA) skin booster containing 20 mg of HA per 1.5 mL and lidocaine, manufactured by Humedix. It is designed for intradermal injection to improve skin quality, specifically targeting skin roughness, photoaging, and signs of aging. In clinical research led by Yonsei University, it has been evaluated as a standalone treatment and in combination with particulated human acellular dermal matrix (phADM) to assess its impact on skin density, volume, and texture.

Brand names: Elravie Balance
Other names: Elravie Balance HA skin booster

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on Elravie Balance.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elravie Balance.

Explore the full profile